Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1eli lillyobesityincretin

Forbes reports Lilly weight-loss candidate produced 56-pound average loss

The figure comes from trial results for an anticipated Eli Lilly obesity drug, reported without further detail in the item.

MH
By Maren Holt · Senior Reporter, GLP-1
Jul 23 03:00 ETSource: Forbes

The wire

  1. 01Forbes reports that an anticipated Eli Lilly weight-loss drug helped participants lose an average of 56 pounds.
  2. 02Average losses of that size would sit at the top of the incretin field and shape prescribing and payer conversations.
  3. 03The item gives no trial name, dose, duration or comparator, so the result should be read against the full published data when available.

From the source

Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average

Read at forbes.com